C
C. Michael Gibson
Researcher at Beth Israel Deaconess Hospital
Publications - 24
Citations - 1358
C. Michael Gibson is an academic researcher from Beth Israel Deaconess Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 14, co-authored 24 publications receiving 1242 citations. Previous affiliations of C. Michael Gibson include Boston Children's Hospital & University of Florida.
Papers
More filters
Journal ArticleDOI
TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction Results of the TIMI 10B Trial
Christopher P. Cannon,C. Michael Gibson,Carolyn H. McCabe,A.A.Jennifer Adgey,Marc J. Schweiger,Rafael F. Sequeira,Gilles Grollier,Robert P. Giugliano,Martin J. Frey,Hiltrud S. Mueller,Richard M. Steingart,W. Douglas Weaver,Frans Van de Werf,Eugene Braunwald +13 more
TL;DR: In this paper, patients with acute ST-elevation myocardial infarction presenting within 12 hours were randomized to receive either a single bolus of 30 or 50 mg TNK-tPA or frontloaded tPA and underwent immediate coronary angiography.
Journal ArticleDOI
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
E. Magnus Ohman,Matthew T. Roe,P. Gabriel Steg,P. Gabriel Steg,Stefan James,Thomas J. Povsic,Jennifer White,Frank W. Rockhold,Alexei N. Plotnikov,Hardi Mundl,John Strony,Xiang Sun,Steen Husted,Michal Tendera,Gilles Montalescot,M. Cecilia Bahit,Diego Ardissino,Héctor Bueno,Marc J. Claeys,Jose C. Nicolau,Jan H. Cornel,Shinya Goto,Róbert Gábor Kiss,Ümit Güray,Duk-Woo Park,Christoph Bode,Robert C. Welsh,C. Michael Gibson +27 more
TL;DR: A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P1y12 inhibitor.
Journal ArticleDOI
Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Edmond Chen,Edmond Chen,John G. Canto,Lori Parsons,Eric D. Peterson,Katherine A. Littrell,Nathan R. Every,C. Michael Gibson,Judith S. Hochman,E. Magnus Ohman,Morris Cheeks,Hal V. Barron,Hal V. Barron +12 more
TL;DR: Among the myocardial infarction patients with cardiogenic shock who underwent IABP placement, mortality rate was significantly lower at high–IAABP volume hospitals compared with low–IABP volume hospitals.
Journal ArticleDOI
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Kausik K. Ray,Christopher P. Cannon,Richard Cairns,David A. Morrow,Nader Rifai,Ajay J. Kirtane,Carolyn H. McCabe,Allan M. Skene,C. Michael Gibson,Paul M. Ridker,Eugene Braunwald,Prove It-Timi Investigators +11 more
TL;DR: Even among patients receiving intensive statin therapy, a lower CRP level was observed in patients with the fewest coronary risk factors present, suggesting that control of multiple risk factors may be a means to further achieve lowerCRP levels.
Journal ArticleDOI
Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis.
Harold L. Dauerman,Donald S. Baim,Donald E. Cutlip,Anthony Sparano,C. Michael Gibson,Richard E. Kuntz,Joseph P. Carrozza,Gary R. Garber,David J. Cohen +8 more
TL;DR: The strategy of atherectomy and adjunctive PTCA for diffuse in-stent restenosis is safe, improves acute angiographic results compared with P TCA alone, and may decrease the need for target vessel revascularization.